Women - CHIPTS - Center for HIV Identification, Prevention and Treatment Services

25Apr

Emerging Issues in Minority Aging Research

Abstract: Emerging Issues in Minority Aging Research will create five different one-day conferences on current NIA priority areas relevant to minority aging research. The conference series goal is to increase the quality, quantity, and relevance to communities of color of NIA-fundable research by providing both junior and senior researchers with new knowledge and greater interest in these emerging issues as applied to minority elderly. This is significant because the U.S. racial and ethnic minority older population is growing rapidly: minorities will increase from 25% to over 40% of the older population between 2020 and 2050. Protecting and improving the health of these elderly requires a highly skilled research workforce with interests and capabilities to produce new and useful knowledge. Yet the number and success of minority researchers funded by NIH is insufficient. The NIA’s Resource Centers for Minority Aging Research (RCMAR) program works to mentor and train junior faculty who conduct research on minority aging to strengthen the next generation of NIA-funded ethnic and racial minority research and researchers. Conferences topics are: Recruitment and retention of elders of color; Access to care & improved outcomes for cognitively impaired minority elderly; Applying the science of behavior change to intervention development for elders of color; Pragmatic intervention trials with minority elders; and Using biological measures of risk in health disparities research with older adults. Each will feature leading scholars on the topic, top scholars on minority aging, and representatives from multiple NIA-funded centers and networks. The programs will disseminate the state of the art on the topic, inform researchers on how existing research can be modified or expanded to be more valid and relevant for minority elders, and provide resources that can be used by researchers to further develop the fields in research with minority elders. They will be held as preconferences to the Gerontological Society of America (GSA) annual scientific meetings with an average of 50 participants each; the majority will be minorities and/or women. The planning committee will be compromised of the confirmed keynote speakers who are leaders in the field and researchers from RCMAR sites with expertise in the topic. The executive committee will be the RCMAR directors group. The project is innovative in the topics covered, the research networks involved, and the synergy with GSA. Program evaluation includes a process evaluation, a retrospective pre/post knowledge and confidence survey, and four-month follow-up survey on conference impacts. The lead investigators are national leaders in minority and aging research who have successfully led previous GSA preconferences. This proposal is a renewal of the previous successful series with new topics but similar objectives of improving the knowledge and interest in emerging issues supported by NIA among those with research agendas in minority aging and raising awareness of minority aging among leading researchers in each topic.

Project Number: 2R13AG023033-16

https://reporter.nih.gov/search/YfhOgZ8LmEm_RStNdvCEhA/project-details/9913950

Contact PI/ Project Leader

WALLACE, STEVEN PAUL,PROFESSOR OF COMM.HEALTH SCI. (SWALLACE@UCLA.EDU)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE:Emerging Issues in Minority Aging Research: This project will create five different one-day conferences on current NIA initiatives that are relevant to minority aging research. The goal of the proposed conference series is to increase the quality, quantity, and relevance to communities of color of NIA-fundable research by providing both junior and senior researchers with new knowledge and greater interest in these emerging issues as they apply to minority elderly.

FOA: PA-18-648/ Study Section: Behavior and Social Science of Aging Study Section[NIA-S]

Project Start Date: 15-September-2019

Project End Date: 31-May-2024

Budget Start Date: 15-September-2019

Budget End Date:31-May-2020

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE ON AGING/ FY Total Cost by IC: $50,000

25Apr

Evaluation of pre-exposure prophylaxis cascade in pregnant and breastfeeding women in Cape Town, South Africa

Abstract: HIV-uninfected pregnant and breastfeeding women in South Africa are at high risk of HIV acquisition despite increased uptake of antiretroviral therapy (ART) and maternal seroconversion during pregnancy and breastfeeding contributes significantly toward pediatric HIV infections. Comprehensive HIV prevention programs that include biomedical interventions, such as pre-exposure prophylaxis (PrEP), could dramatically reduce HIV incidence in pregnant and breastfeeding women in high HIV incidence areas and reduce vertical HIV transmission. The overarching goal of this proposal is to evaluate the feasibility and acceptability of integrating PrEP into antenatal and postnatal care, to describe the cascade in women initiating PrEP in this setting, and to evaluate the reasons for attrition along the PrEP cascade in a cohort of pregnant and breastfeeding women Candidate: I am an HIV epidemiologist with a background in HIV research and program development, implementation in Africa. I am applying for a five-year Fogarty IRSDA K01 award to obtain training, mentorship, and research experience to become an independent investigator capable of obtaining R01 funding. Mentoring: I have put together an exceptional multi-disciplinary mentoring team with extensive experience in HIV prevention research in South Africa that integrates clinical research, epidemiology, PrEP and qualitative methods. Drs. Thomas Coates (UCLA) and Landon Myer (University of Cape Town, South Africa) will serve as co-Primary mentors and bring complementary expertise in behavioral science and clinical trials. In addition to my two Primary mentors, my co-mentors provide expertise in specific content areas and methodologies and are based in both the U.S. and South Africa. My co-mentorship team includes: Dr. Pamina Gorbach (U.S.-based, behavioural epidemiologist with significant experience in mixed methods research, Dr. Linda-Gail Bekker (SA-based, clinical trials, PrEP and research in young women). Training: Specific training in clinical trials, advanced biostatistics, behavioural science and mixed methods analysis, will be achieved through intensive mentored training, coursework, workshops and and primary research in South Africa. Guided by my mentorship team, these training and research experiences will establish my independent investigator career as an expert in research in pregnant and breastfeeding women in low resource settings. Research: The specific aims are to: (1) Evaluate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services; (2) Describe the PrEP cascade of initiation, retention, and adherence in a cohort of HIV-uninfected pregnant and breastfeeding women, (3) Evaluate attrition and associated factors across the PrEP cascade. The results from our study will provide a model to implement WHO guidance and scale-up PrEP delivery in pregnant and breastfeeding women at risk of HIV and contribute to the elimination of vertical HIV transmission. We will use the formative research to apply for a R01 grant to evaluate interventions to improve retention in the PrEP cascade in a larger cohort of pregnant and breastfeeding women.

Project Number: 5K01TW011187-02

https://reporter.nih.gov/search/07mRB8oPokuMg0OWfAXBVA/project-details/9789716

Contact PI/ Project Leader

JOSEPH DAVEY, DVORA POSTDOCTORAL FELLOW (dvoradavey@ucla.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: HIV-negative pregnant and breastfeeding women in South Africa are at high-risk of HIV. Pre-exposure prophylaxis (PrEP) is safe and effective at preventing HIV. Our study will evaluate: (1) Acceptability & feasibility of integrating PrEP into ante and postnatal care, (2) the PrEP cascade (initiation, retention, adherence) and (3) Loss to follow up and factors associated with loss in a cascade in 200 pregnant/breastfeeding women.

FOA:PAR-18-540/ Study Section: International and Cooperative Projects – 1 Study Section[ICP1]

Project Start Date: 21-September-2018

Project End Date: 31-January-2023

Budget Start Date: 01-April-2019

Budget End Date: 31-January-2020

NIH Categorical Spending

Funding IC: FOGARTY INTERNATIONAL CENTER/ FY Total Cost by IC: $139,018

25Apr

Innovative strategies to increase ART Initiation and viral suppression among HIV+ men in Malawi

Abstract: Men continue to be missed by HIV testing and treatment services. Index partner testing is a critical strategy for reaching men. Index HIV self-testing (HIVST), whereby ART clients take HIVST kits home to their sexual partners for testing, is a new strategy that dramatically increases index testing among men, and is being taken to scale across Malawi. However, only 25% of men identified as HIV-positive through Index HIVST initiate ART after 6- months. Innovative strategies to increase ART initiation and retention among men are urgently needed. The overarching goal of the proposed K01 is to develop and pilot a home-based ART intervention (ART initiation + 3-months ART care) to increase ART initiation (primary outcome) and 6-month viral suppression (secondary outcome) among men who test HIV-positive through Index HIVST in Malawi. Candidate: I am a social scientist with a background in HIV research in sub-Saharan Africa. My long-term goal is to transition from observational social science to clinical trials research in innovative HIV service delivery models among hard-to-reach populations, such as men. I am applying for a five-year K01 award to obtain training, mentorship, and research experience. Mentoring: I have an exceptional multi-disciplinary mentoring team with extensive experience in HIV care and management and clinical trials in the region. The team has complementary expertise in social science and clinical trials in HIV service delivery models (Dr. Thomas Coates – Primary Mentor), best practices in HIV care and management and differentiated models of care in Malawi (Drs. Judith Currier and Risa Hoffman), scalability and sustainability of interventions (Dr. Sundeep Gupta – Malawi-based), and advanced biostatistics (Dr. Ron Brookmyer). Career Development: To achieve my long-term goals, we have developed a detail plan to build skills in four additional areas: (1) best clinical practices for ART care and maintenance; (2) clinical trials in novel approaches to HIV service delivery; (3) advanced statistical methods; and (4) ethics in clinical trials research in low-resource settings. Research Activities: The specific aims accompanying the career development plan are to: (1) Develop a home-based ART intervention for male partners tested through Index HIVST, using in-depth interviews with male Index HIVST users (n=15-20) and their partners (n=15-20), and focus group discussions with key informants (n=18-30). (2) Determine the potential effectiveness of home-based ART versus standard facility-based ART (on ART initiation (primary outcome) and 6-month viral suppression (secondary outcome) among male Index HIVST users in a pilot trial with 200 HIV-positive men. Expected Outcomes: Results from this study will inform definitive trial to test home-based ART services for men identified as HIV-positive through index HIVST strategies. The project will also give me the additional skillsets needed to become an independent investigator in clinical trials.

Project Number: 1K01TW011484-01

https://reporter.nih.gov/search/lzNvPVXZdEyO9lcrU7nKLQ/project-details/9889473

Contact PI/ Project Leader

DOVEL, KATHRYN L, POSTDOCTORAL FELLOW (KDovel@mednet.ucla.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: Men in sub-Saharan Africa who test HIV-positive continue to have poor ART initiation and retention outcomes. By developing and piloting a home-based ART intervention for men who use index HIV self-testing (HIVST) strategies, the proposed project will provide additional knowledge on how to best reach men with HIV services across the testing and treatment continuum. The project has the potential to improve public health by engaging HIV-positive men across the cascade, a critical population to curbing the HIV epidemic.

FOA: PAR-18-540/ Study Section: International and Cooperative Projects – 1 Study Section[ICP1]

Project Start Date: 16-September-2019

Project End Date: 30-June-2024

Budget Start Date: 16-September-2019

Budget End Date:30-June-2020

NIH Categorical Spending

Funding IC: FOGARTY INTERNATIONAL CENTER/ FY Total Cost by IC: $145,233

13Apr

Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis

Abstract: The proposed project is designed to evaluate the effectiveness of cefixime (400mg, twice a day, for 10 days) compared to benzathine penicillin G (2.4 million units, intramuscularly) in patients with and without HIV infection. Syphilis rates have been increasing both in the US and internationally. Incidence is higher among men-who-have-sex-with-men and more importantly in individuals with HIV infection. Currently, penicillin is used to treat syphilis in patients with and without HIV infection. Doxycycline, tetracycline and ceftriaxone are alternative treatments for non-pregnant patients who are allergic to penicillin. Existing treatment alternatives are based on clinical experience, a limited number of small clinical trials, and case series, but each poses clinical challenges. New, safe and efficacious antibiotic treatment options are needed. In this proposal, we will build upon our successful pilot study to conduct a randomized, multisite, open-label, non- inferiority clinical trial to evaluate the effectiveness of cefixime (400mg, twice a day, for 10 days) compared to benzathine penicillin G (2.4 million units, intramuscularly) in patients with and without HIV infection. We will enroll 400 participants with early syphilis infection from 9 clinical sites in the U.S. and Peru. We will follow the participants to monitor clinical progress and serological response (RPR titer) every 3 months for 9 months. Our hypothesis is that cefixime will be non-inferior to penicillin in treating syphilis, shown as a 4-fold decrease in RPR titer from enrollment to 6-months after treatment administration. These are the two specific aims of our proposal. AIM 1: Evaluate the effectiveness of cefixime in the treatment of early syphilis when compared to benzathine penicillin G. AIM 2: Determine the predictors of treatment failure among participants. The 5 year project has 4 phases. Phase I will last 9 months and will involve the development of study instruments, staff training on recruitment, enrollment, and data collection. Phase II will last 36 months and will involve recruitment and enrollment of patients. Phase III which will last 45 months, but will start simultaneously as stage II, and will include the patient follow-up period. Phase IV will last 6 months and in that time, the data will be analyzed and disseminated.

Project Number: 7R01AI155217-02

https://reporter.nih.gov/search/YayN4XwnBUe4QIvlEb1gsg/project-details/10392825

Contact PI/ Project Leader

KLAUSNER, JEFFREY DAVID, CLINICAL PROFESSOR (jdklausner@med.usc.edu)

Organization

UNIVERSITY OF SOUTHERN CALIFORNIA

PUBLIC HEALTH RELEVANCE: In the proposed study, we will examine the effectiveness of oral cefixime 400 mg twice-daily for 10 days (compared to injectable single dose benzathine penicillin G) in treating syphilis among people with and without HIV infection. The results of this clinical trial might identify cefixime as a novel alternative treatment for syphilis that is useful for people living with HIV infection, in patients with penicillin allergy or in settings of penicillin shortage. We will also describe predictors of syphilis treatment failure among people with and without HIV.

FOA: PA-18-590/ Study Section: HIV Coinfections and HIV Associated Cancers Study Section[HCAC]

Project Start Date: 13-July-2020

Project End Date: 30-June-2025

Budget Start Date: 01-July-2021

Budget End Date: 30-June-2022

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/ FY Total Cost by IC: $665,080

13Apr

Clinical study of STI screening to prevent adverse birth and newborn outcomes

Abstract: Infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV) during pregnancy are associated with premature rupture of membranes, preterm labor and delivery, low birth weight, congenital infections, perinatal death and mother-to-child transmission of HIV infection. Sexually transmitted infections (STIs) like these are common in pregnant women globally, but often go undiagnosed; recent work by our group found a 41% STI prevalence amongst HIV-infected pregnant women, of which 64% of infections were asymptomatic. Recent research suggests the vaginal microbiome may play a critical role in STI acquisition, persistence and treatment outcomes. Our pilot work has shown that diagnostic testing for CT, NG, and TV in antenatal care services for HIV-infected pregnant women in South Africa is highly acceptable and feasible; however, our work has made clear that evaluating the impact and cost effectiveness of different diagnostic screening strategies that optimally decrease the burden of STIs during pregnancy and at time-of-delivery is urgently needed. Furthermore, our findings highlight that biological factors that increase the risk for STI persistence and/or treatment failures must be further investigated. In response to the need to 1) identify optimal, cost-effective screening strategies that decrease the burden of STIs during pregnancy and reduce adverse birth outcomes, 2) provide evidence to update WHO’s syndromic management guidelines, and 3) elucidate the role of the vaginal microbiome in STI treatment outcomes, we propose a novel, highly innovative study with the following three Aims: Aim 1: Evaluate 3 different screening strategies to decrease the burden of CT/NG/TV among pregnant women, and reduce adverse birth outcomes. Aim 2: Evaluate cost per pregnant woman screened and treated, cost of adverse birth outcomes, and cost-effectiveness per STI and disability-adjusted life-year (DALY) averted. Aim 3: Investigate the relationship between the vaginal microbiome and persistent Chlamydial infections in pregnant women. Our proposed 5-year study will enroll 1250 HIV-infected and 1250 uninfected pregnant women from three large ANC clinics in Tshwane District, South Africa, as well as their ~2500 neonates and up to 834 male partners. Our research team, led by established researchers, has significant expertise and experience in all aspects of the proposed study. Our multi-institutional collaborations will allow us to leverage unique implementation platforms and resources, and allow for rapid dissemination of findings to South African and global stakeholders.

Project Number: 1R01AI149339-01

https://chipts.ucla.edu/wp-admin/post-new.php?post_type=pendari_portfolio

Contact PI/ Project Leader

KLAUSNER, JEFFREY DAVID, CLINICAL PROFESSOR (jdklausner@med.usc.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: This effectiveness trial will increase understanding of the value and cost-effectiveness of diagnostic screening for sexually transmitted infections (STIs) among pregnant women in low and middle-income countries, to reduce adverse pregnancy and infant outcomes. Further, results from this study will provide important data on the role of the vaginal microbiome in Chlamydia trachomatis (CT) testing outcomes and further rationale for studying the vaginal microbiome in pregnant women with CT treatment failure. Together, findings from this R01 are likely to inform changes to STI screening and treatment guidelines in low-middle income countries globally.

FOA: PA-19-055/ Study Section: Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section[IRAP]

Project Start Date: 07-January-2020

Project End Date: 31-December-2024

Budget Start Date: 07-January-2020

Budget End Date: 31-December-2020

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES/ FY Total Cost by IC: $811,925

12Apr

Evaluating the PrEP cascade in HIV-negative pregnant and breastfeeding women in South Africa (PrEP-PP)

Abstract: HIV-negative pregnant and breastfeeding women in South Africa are at extremely high risk of HIV acquisition despite increased access to and initiation of antiretroviral therapy (ART) in South Africa. We urgently need effective interventions to reduce HIV incidence in pregnant and breastfeeding women. Currently PrEP is one of the only female controlled methods that is effective for preventing HIV acquisition. PrEP-PP is a study of pre-exposure prophylaxis (PrEP) among HIV-1 seronegative Pregnant and Postpartum women in two South African urban primary health care facilities. Effective use of PrEP could contribute to eliminating maternal HIV acquisition, and hence eliminating mother to child HIV transmission (MTCT). However, PrEP efficacy requires adherence during periods of sexual activity and adherence requires PrEP access, awareness and counseling. Currently, a major obstacle in the field is the lack of knowledge of women’s initiation, retention and adherence to PrEP during pregnancy and breastfeeding periods in Africa. Now is the time to evaluate how best to provide PrEP to vulnerable pregnant and breastfeeding women as WHO recently developed guidelines for providing PrEP in pregnancy and breastfeeding women but there are limited data on acceptability, initiation and adherence in pregnant and breastfeeding women in Africa where the burden of HIV is greatest. Our study will focus on the following specific aims: 1. Determine the distribution of women across the PrEP cascade (initiation, retention, and adherence) and outcomes (HIV acquisition, transmission, and adverse events) in a cohort of pregnant and breastfeeding women in Cape Town, South Africa 2. Evaluate patient and provider-level factors associated with the PrEP cascade (initiation, retention and adherence) using quantitative and qualitative approaches 3. Apply an established mathematical model to simulate the impact of improvement in the PrEP cascade on HIV infections averted (maternal and perinatal) Our PrEP-PP study is urgent and essential to understand the PrEP cascade in pregnant and breastfeeding women in South Africa and to identify factors associated with PrEP initiation and adherence to develop interventions to ensure that everyone in this at-risk population can benefit from PrEP. The results from the PrEP-PP study will provide a model for the South African Government, and other Governments in the region, to scale up PrEP delivery among pregnant and breastfeeding women at risk of HIV acquisition and perinatal transmission and contribute to the elimination of perinatal HIV transmission.

Project Number: 1R01MH116771-01A1

https://reporter.nih.gov/search/dkK25PIoW0KfsaDd4N5FHw/project-details/9623865

Contact PI/ Project Leader

COATES, THOMAS J., PROFESSOR IN RESIDENCE (tcoates@mednet.ucla.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: HIV-negative pregnant and breastfeeding women in South Africa (SA) are populations at very high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) is one of the only female controlled methods that can prevent HIV acquisition. Our study, PrEP-PP, will evaluate the PrEP cascade ( PrEP initiation, retention, adherence) and patient and provider-level factors associated with the PrEP cascade to inform future PrEP programs.

FOA: PA-16-160 / Study Section: Behavioral and Social Science Approaches to Preventing HIV/AIDS Study Section[BSPH]

Project Start Date: 15-September-2018

Project End Date: 30-June-2023

Budget Start Date: 15-September-2018

Budget End Date: 30-June-2019

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE OF MENTAL HEALTH / FY Total Cost by IC: $579,553

11Apr

Engaging men through HIV self-test and differentiated care models to increase ART initiation and viral suppression in Malawi

Project Number: 1R01MH122308-01A1

https://reporter.nih.gov/search/C5ftR11Y1USYYpNuXQjMzg/project-details/10013734

Contact PI/ Project Leader

COATES, THOMAS J., PROFESSOR IN RESIDENCE (tcoates@mednet.ucla.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: Men in sub-Saharan Africa who test HIV-positive continue to have poor ART initiation and retention outcomes. The proposed project will test a home-based ART intervention for men who use HIV self-testing (HIVST) strategies compared to facility-based ART. Findings will provide essential information on how to best reach men across the testing and treatment continuum, a critical step to curbing the HIV epidemic.

FOA: PA-19-042 / Study Section: HIV/AIDS Intra- and Inter-personal Determinants and Behavioral Interventions Study Section[HIBI]

Project Start Date: 17-June-2020

Project End Date: 31-May-2025

Budget Start Date: 17-June-2020

Budget End Date: 31-May-2021

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE OF MENTAL HEALTH / FY Total Cost by IC: $643,041

11Apr

Bringing South African Men into HIV Counseling and Testing (HCT) and Care

Abstract: The ultimate objective of this research is to provide evidence-based strategies to improve treatment of HIV+ men. Treatment as prevention (TasP) can only work through a three step process: (1) Testing a significant proportion of the population, (2) linkage to care and (3) maintaining in care a significant proportion of HIV+ individuals to the point of viral suppression. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. We propose a study that combines structural and individual level interventions and integrates the results to address our overall objective of maintenance in care to the point of viral suppression. Aim 1: In a cluster-randomized study, we will investigate whether male-centered mobilization and testing increases the population-level percentage of men who have been tested (within the last 12 months) by more than 10 absolute percentage points. Aim 2: In the individually-randomized design, we will investigate whether POC CD4 testing and individualized case management improves linkage to care (immediately following diagnosis) and viral suppression (12 months later) over POC CD4 testing alone and standard of care. Aim 3: Integrate the results of the two trial components (Aims 1 and 2) to evaluate the joint effect of the interventions on the percentage of HIV+ men who are effectively tested, linked to care and maintained with undetectable VL. The benefits of increased testing, linkage to and maintenance in care for men would be enormous. Men would remain healthier longer, could work and support their families, contribute to rather than deplete household economic resources, raise their children, and they would be less likely to transmit HIV to female partners

Project Number: 5R01MH105534-05

https://reporter.nih.gov/search/VniB9auLBEWQm8hAmLPNVg/project-details/9728038

Contact PI/ Project Leader

COATES, THOMAS J., PROFESSOR IN RESIDENCE (tcoates@mednet.ucla.edu)

Organization

UNIVERSITY OF CALIFORNIA LOS ANGELES

PUBLIC HEALTH RELEVANCE: Men in sub-Saharan Africa are less likely than women to get tested for HIV, less likely to present for treatment, less likely to be maintained in treatment, moe likely to have detectable viral load (VL), more likely to transmit HIV with unprotected intercourse and more likely to progress to AIDS and die sooner from HIV. As such, community-based HIV counseling and testing strategies that are responsive and attractive to men are urgently required. This research will evaluate innovative strategies to test for HIV and diagnose black African men and successfully link them to care and maintain them in care, which may reduce their likelihood of transmitting HIV and have a beneficial impact on their individual health, as wel as the well-being of their partners, children, families, and communities.

FOA: PA-13-302 / Study Section: Special Emphasis Panel[ZRG1-AARR-F(02)M]

Project Start Date: 07-July-2015

Project End Date: 30-April-2022

Budget Start Date: 01-May-2019

Budget End Date: 30-April-2022

NIH Categorical Spending

Funding IC: NATIONAL INSTITUTE OF MENTAL HEALTH / FY Total Cost by IC: $511,341

4Apr

Innovative HIV Testing Strategy for Middle-to-Upper Income Men in a Resource Limited Setting

Abstract:In Botswana, the setting of the proposed study, nearly one in five adults are living with HIV. Men in Botswana over age 40, the focus on the present research, show relatively high levels of HIV prevalence and risk behavior, and low levels of HIV testing. Moreover, higher income is associated with increased risk of being HIV-positive in sub-Saharan Africa (SSA). The proposed research will use mixed methods to develop an intervention that de- stigmatizes and encourages HIV testing among men of middle-to-higher socio- economic status (SES) in Gaborone, Botswana. We will focus on increasing HIV testing among men of higher SES. Fear of being stigmatized among financially secure men in employment in Botswana may contribute to low HIV testing uptake. The Specific Aims are: Aim 1: To initially conduct formative qualitative work to explore the role of stigma on low HIV testing uptake among 20 men via face to face interviews, and then to obtain feedback about potential interventions using asynchronous online focus group discussion among 40 men all with relatively high socio-economic status (SES) in Botswana. Aim 2: To develop and conduct a small pilot test of a local, culturally appropriate HIV testing strategy targeting 100 men in the higher-SES in Botswana. Hypothesis: At least 60% of men will access the new HIV testing strategy, equivalent to a ~20% point increase above testing strategies not tailored to men. Aim 3: To build capacity for HIV stigma and related behavioral research by conducting focused workshops in Botswana. To reach the remaining 10-10-10, it is essential to develop differentiated, tailored approaches for risk groups, such as men of relatively higher SES, that are untouched by existing prevention and testing frameworks in countries of high HIV prevalence.!

Project Number:5R21TW011069-02

https://reporter.nih.gov/search/ukRDruCWsESODyaoaOckJg/project-details/9730678

Contact PI/ Project Leader

BOGART, LAURA M, SENIOR BEHAVIORAL SCIENTIST (LBOGART@RAND.ORG)

MOSEPELE, MOSEPELE, SENIOR LECTURER (mosepelemosepele@gmail.com)

Organization

UNIVERSITY OF BOTSWANA

PUBLIC HEALTH RELEVANCE: In Botswana, the setting of the proposed study, nearly one in five adults are living with HIV, and men over age 40, especially those of higher income, are at particularly high HIV risk due to concurrent multiple partnerships and low rates of HIV testing. We propose to explore qualitatively how stigma in the context of masculine gender role norms may be a barrier to HIV testing among men over age 40 years of higher socioeconomic status in Botswana, and use these results to develop and pilot an innovative HIV testing strategy through major employers that is tailored to men.

FOA: PAR-17-474/ Study Section: Special Emphasis Panel[ZRG1-AARR-N(56)R]

Project Start Date: 01-July-2018

Project End Date:30-April-2022

Budget Start Date: 01-May-2019

Budget End Date: 30-April-2022

NIH Categorical Spending

Funding IC: FOGARTY INTERNATIONAL CENTER / FY Total Cost by IC:$106,708

30Oct

HPTN-083

Abstract: Cabotegravir LA (CAB LA) is a long-acting injectable integrase inhibitor, also known as GSK 1265744 LA or 744 LA. This is a Phase 2b/3 study designed to establish the efficacy of CAB LA for pre-exposure prophylaxis (PrEP) in HIV-uninfected men who have sex with men (MSM) and in transgender women (TGW). Small single-dose and multiple-dose studies and Phase 2a safety/tolerability studies have been performed for CAB LA. This PrEP efficacy study is the next developmental investigation of CAB LA in healthy, HIV-uninfected MSM and TGW. CAB LA is the first antiretroviral (ARV) drug being studied as an intervention for HIV prevention prior to regulatory approval of the drug for HIV treatment. A parallel development program for use of cabotegravir (oral and injectable) for treatment of HIV-infected individuals is currently in Phase 2b studies with a salutary safety and efficacy profile to date.

To enroll in HPTN-083, click here for more information.

Project Number: 5um1ai068619-11

1 2 3 Next page

Posts classified under: Women